Introduction and Maintenance of Still Eating Protein Blends in Support of Infant Nutritional Goals
NCT ID: NCT03667118
Last Updated: 2019-03-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
705 participants
INTERVENTIONAL
2017-06-18
2017-10-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Show that the food supplement is well tolerated and safe to feed to infants;
* Find out how often parents/caregivers feed their infants the food supplement;
* Find out how parents/caregivers usually add the food supplement to infants' regular solid or liquid food; and
* Learn what aspects of the food supplement are more or less attractive to infants and to parents/caregivers.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Double-blind Randomized Controlled Trial of a Thickened Amino-acid-based Formula in Children Allergic to Cow's Milk and to Protein Hydrolysates
NCT01940068
Growth, Safety and Tolerance of a Hydrolyzed Protein Infant Formula
NCT05618704
Infant Formula in Infants and Children With Cow's Milk Allergy
NCT06456541
Nutrition Sufficiency, Allergy Efficacy and Safety of Neocate Jr in Children With Food Protein Allergy
NCT05406141
Evaluation of the Efficacy of a New Formula in Infants With Cow's Milk Protein Allergy
NCT01998074
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
During the intervention period, infants randomized to the food supplement are fed a once daily, individual packet of the food supplement mixed into liquid (e.g., breast milk, infant formula) or solid (e.g., applesauce, pureed carrots) foods being fed to the infant. The food supplement is a blend of 16 common allergenic proteins (\[oat, milk, egg, sesame, wheat\] \[almond cashew, hazelnut, peanut, pecan, pistachios, soy, walnut\] \[cod, shrimp, salmon\]) combined with 400 IU of Vitamin D3. Parents complete a daily diary about any reactions or symptoms within 2 hours of ingesting the food supplement. Infants randomized to the placebo are also fed a once daily individual packet of the placebo mixed into liquid or solid foods being fed to the infant. Parents also complete a daily diary about any reactions or symptoms within 2 hours of ingesting the placebo.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Food Supplement
Infants who received the active food supplement powder
Food Supplement
A powder blend of 16 common allergenic proteins (\[oat, milk, egg, sesame, wheat\] \[almond cashew, hazelnut, peanut, pecan, pistachios, soy, walnut\] \[cod, shrimp, salmon\]) combined with 400 IU of Vitamin D3
Placebo
Infants who received the placebo powder
Food Supplement
A powder blend of 16 common allergenic proteins (\[oat, milk, egg, sesame, wheat\] \[almond cashew, hazelnut, peanut, pecan, pistachios, soy, walnut\] \[cod, shrimp, salmon\]) combined with 400 IU of Vitamin D3
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Food Supplement
A powder blend of 16 common allergenic proteins (\[oat, milk, egg, sesame, wheat\] \[almond cashew, hazelnut, peanut, pecan, pistachios, soy, walnut\] \[cod, shrimp, salmon\]) combined with 400 IU of Vitamin D3
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Any parent/caregiver who cannot understand or write English.
* A parent/caregiver who is in prison.
* Any infant who
* Has a previous or current diagnosis of food allergy, made by a board-certified allergy and immunology specialist;
* Was born before 37 weeks of pregnancy (premature birth);
* Has severe eczema, as determined by two parent/caregiver questions:
1. During the past 6-11months, have you been told by a doctor or other health professional that your infant has eczema or any kind of skin allergy? (National Health Interview Survey, 2012) If yes, go to Question 2.
2. Would you describe (his/her) eczema or skin allergy as mild, moderate, or severe? (National Survey of Children's Health, 2007) If described as severe, infant is excluded.
* Has a current serious, chronic condition, as measured by:
1. Does you infant have a health condition that has lasted for more than three (3) months? If yes, go to Question 2.
2. Has your infant been hospitalized more than 2 times since birth for this condition? If yes to Question 1 and 2, infant is excluded.
* If a parent/caregiver has multiple birth infants (e.g., twins), only one eligible infant will be selected.
* Any person who works for Before Brands or who has a family member working for Before Brands.
5 Months
11 Months
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Northwestern University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jane Holl
Director, Center for Healthcare Studies
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jane L Holl, MD MPH
Role: PRINCIPAL_INVESTIGATOR
Professor of Pediatrics, Feinberg School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jane L Holl
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STU00205862
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.